

1 Megan A. Maitia, Bar No. 285271
2 megan@summaLLP.com
3 Jennifer L. Williams, Bar No. 268782
4 jenn@summallp.com
5 SUMMA LLP
6 1010 Sycamore Avenue, Unit 117
South Pasadena, California 91030
Telephone: (213) 260-9452/54
Facsimile: (213) 835-0939

7
8 Attorneys for Plaintiffs

9 **UNITED STATES DISTRICT COURT**

10 **CENTRAL DISTRICT OF CALIFORNIA – WESTERN DIVISION**

11 WEIRD SCIENCE LLC and WILLIAM
12 ANDERSON WITTEKIND, derivatively
on behalf of RENOVARO BIOSCIENCES,
13 INC.

Case No.: 2:24-cv-00645-HDV-MRW

14 Plaintiff,
15 v.
16 RENÉ SINDLEV, MARK DYBUL,
17 GREGG ALTON, JAMES SAPIRSTEIN,
18 JAYNE McNICOL, HENRIK
19 GRØNFELDT-SØRENSEN, CAROL L.
BROSGART, AVRAM MILLER, KAREN
20 BRINK, YALLA YALLA LTD., RS
GROUP APS, RS BIO APS, PASECO
21 APS, OLE ABILDGAARD, K&L GATES
22 LLP, CLAYTON E. PARKER, LINCOLN
PARK CAPITAL FUND LLC, DOES 1-
23 10,
24 Defendants,
25 and
26 RENOVARO BIOSCIENCES INC.,

**NOTICE OF SUBSEQUENT
EVENT RELATED TO PENDING
MOTION TO DISMISS**

Hearing Held: October 3, 2024 (motion
under submission)

27 Nominal Defendant.
28

**NOTICE OF SUBSEQUENT EVENT
RELATED TO PENDING MOTION TO DISMISS**

Pending before the Court is a motion to dismiss (Dkt. 36) filed by the Renovaro Board Defendants René Sindlev, Mark Dybul, Gregg Alton, Carol Brosgart, Henrik Grønfeldt-Sørensen, James Sapirstein, and Jayne McNicol, all of whom are represented by the law firm Vedder Price. The motion has been fully briefed (Dkt. 39, 41.) The Court held a hearing on October 3, 2024 and took the matter under submission.

On October 16, 2024, Renovaro publicly announced information that goes to the heart of this derivative case and the pending motion to dismiss: Chairman René Sindlev threatened the remaining Board Defendants with legal action unless they resigned and claimed to have the support of Renovaro stockholders owning 107 million shares of Renovaro’s common stock outstanding to remove the directors by a shareholder vote. The Board Defendants (including the sole director on the Special Litigation Committee purportedly investigating Plaintiffs’ demands) subsequently resigned, and Sindlev installed a new, hand-picked Board of Directors and then resigned himself. This was done without disclosures required by SEC regulations.

The announced information and related legal issues are further explained below. Vedder Price has ignored inquiries about this new information. Plaintiff's counsel therefore brings the information to the Court's attention through this notice and is available for subsequent briefing and/or a status conference, at the Court's discretion.

Summary of subsequent events and related context.

- On April 11, 2024, Michael J. Quinn, legal counsel for Rene Sindlev and the other Board Defendants, submitted a declaration to the court declaring, under penalty of perjury, that “[i]n direct response to Plaintiffs’ demand letter, the Renovaro Board appointed a Special Committee of independent directors, Leni Boeren and Ruud Hendricks” and that “[t]he Special Committee retained Stradling Yocca Carlson & Rauth LLP as counsel, who has begun an investigation into Plaintiffs’ demands.” (Dkt. 24-1.)

- On July 3, 2024, [RENB filed a Form 8-K](#) reporting that Leni Boeren gave notice of her resignation as a director of RENB on June 27, 2024, effective as of such date. According to the Form 8-K, “Ms. Boeren served as chair of the Company’s special litigation committee.”
- On October 10, 2024, [RENB filed its Form 10-K](#) for the year ended June 30, 2024, in which it disclosed “the Board of Directors initially formed a Special Committee (“Special Committee”) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson & Rauth LLP as its counsel to investigate the issues identified in the demand letters. The Special Committee’s investigation is ongoing.”
- On October 16, 2024, [RENB filed a Form 8-K](#) reporting that: (i) on October 11, 2024, the day after RENB filed its Form 10-K, which was signed by all of RENB’s directors, Avram Miller and Ruud Hendricks, the sole remaining director on the Special Committee, resigned as directors; (ii) on October 12, 2024, Mark Dybul, Karen Brink and James Sapirstein resigned as directors; (iii) on October 13, 2024, Greg Alton, Carol Brosgart and Jayne McNicol resigned as directors; (iv) on October 14, 2024 Rene Sindlev filled five vacant director seats with David Weinstein, Maurice van Tilburg, James A. McNulty, Douglas W. Calder and Mark A. Collins Ph.D.; and (v) on October 15, 2024 Mr. Sindlev resigned as chairman of the board.
- A [resignation letter from Mr. Sapirstein](#) and a [resignation letter from Mr. Alton, Ms. Brosgart and Ms. McNicol](#) were attached as exhibits to the October 16, 2024 Form 8-K. Both resignation letters indicate that Mr. Sindlev represented to the resigning directors that he had sought and received support from stockholders owning 107 million shares to remove all the directors. The letter from Mr. Alton, Ms. Brosgart and Ms. McNicol stated that Mr. Sindlev had threatened legal action against the directors if they did not resign.

1 ***Summary of legal issues related to pending motion to dismiss.***

- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- Rule 13d-2(a) requires a Schedule 13D reporting person to file an amendment within two business days disclosing any material change in the facts set forth in the Schedule 13D.
 - Item 4(d) of Schedule 13D requires a description of “any plans or proposals which the reporting persons may have which relate to or would result in . . . any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or fill any vacancies on the board” . . . and Item 4(j) requires a description of “any action similar to any of those enumerated above.”
 - Mr. Sindlev and his holding company RS Bio are Schedule 13D reporting persons. Based on the disclosures in the Form 8-K and the resignation letters, Mr. Sindlev was communicating with RENB’s stockholders to garner support to remove RENB’s directors before October 11, 2024 and that he threatened to cause RENB stockholders to remove the directors if they did not resign. Mr. Sindlev’s threats caused each of RENB’s directors to resign and Mr. Sindlev filled the vacancies with his own slate before resigning himself.
 - Mr. Sindlev was required to disclose his plans to remove and replace RENB’s directors no later than two business days after he formulated this plan. Based on the dates in the Form 8-K and the resignation letters attached as exhibits, Mr. Sindlev must have formulated this plan earlier than October 11, 2024, the date of the first director resignation.
 - Mr. Sindlev’s failure to file an amendment to his Schedule 13D was and remains a violation of Rule 13d-2, as a plan to unseat the entire board of directors is the epitome of a material change that should have been disclosed to the Company’s stockholders.
 - Plaintiffs have asserted that, for the reasons set forth in the First Amended Complaint, Mr. Abildgaard does not qualify to report his ownership on Schedule

1 13G (Dkt. 31 ¶¶ 96-99), and that Mr. Sindlev has given testimony under oath
2 stating that Mr. Abildgaard promotes Renovaro's stock to other Danish investors
3 (Dkt. 31 ¶ 48 and n.45). Because Mr. Abildgaard continues to report on Schedule
4 13G, he needed to file a Schedule 13D within five business days of his
5 involvement in Sindlev's plan because Abildgaard held his securities in
6 connection with or as a participant in any transaction having the purpose or effect
7 or changing or influencing control of RENB. This is another basis of a Section
8 13(d) group between Sindlev, Abildgaard, and others making up the stockholders
9 of the 107 million shares.

- 10 • Section 14(f) of the 1934 Act and Rule 14f-1 thereunder require an issuer to file a
11 Schedule 14F-1 with the SEC and transmit it to the stockholders at least 10 days
12 before the directors take office if those directors will constitute a majority of the
13 directors and are to be elected other than at a meeting of stockholders pursuant to
14 any arrangement or understanding with a person subject to Section 13(d). RENB
15 has not filed a Schedule 14F-1 and Plaintiffs have not received one.
16 • Mr. Sindlev is a Section 13D reporting person and his arrangement in replacing
17 the entire board with his own designees without a meeting of stockholders
18 triggered a Schedule 14F-1 filing obligation by RENB. As a result, Mr. Sindlev
19 not only violated Section 13(d) and Rule 13d-2(a), but he caused RENB to violate
20 Section 14(f) and Rule 14f-1.

21 On Wednesday morning, October 16, 2024, undersigned counsel emailed Michael
22 Quinn and Philip Tankovich at Vedder Price to ask whether they still represented the
23 Board Defendants considering the resignations and apparent conflicts between Sindlev and
24 the other Board Defendants. As of the date and time of this filing, Vedder Prices has not
25 responded to the email.

1 Dated: October 22, 2024

Respectfully submitted,

2
3 By: Megan Maitia

4 Megan A. Maitia
5 Jennifer L. Williams
SUMMA LLP

6 Attorneys for Plaintiffs
7 Weird Science LLC and
8 William Anderson Wittekind

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28